Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions
Michael A Singer,1 Steven R Cohen,2 Sylvia L Groth,3 Salman Porbandarwalla21Medical Center Ophthalmology Associates (MCOA), San Antonio, Texas, USA; 2Department of Ophthalmology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA; 3University of Minnesota Medical Schoo...
Saved in:
Main Authors: | Singer MA, Cohen SR, Groth SL, Porbandarwalla S |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2013
|
Subjects: | |
Online Access: | https://doaj.org/article/da4a9277206a42c9bea4f22a7cc3547e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
by: Keane PA, et al.
Published: (2011) -
Effects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion
by: Eltutar K, et al.
Published: (2013) -
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
by: Juan Carlos Mesa Gutiérrez, et al.
Published: (2008) -
The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
by: Ivanovska Adjievska B, et al.
Published: (2017) -
Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2
by: Narayanan R, et al.
Published: (2016)